Garadacimab (andembry) approved to prevent angioedema attacks
24 January 2025
The UK medicines regulator has approved garadacimab (andembry) to prevent angioedema attacks in people with hereditary angioedema (HAE).
HAE is a rare genetic condition that causes episodes of swelling in the face, limbs, abdomen, and airways. These attacks can be debilitating and potentially life-threatening.
Garadacimab is a monoclonal antibody that blocks the action of a protein called kallikrein, which is involved in the development of angioedema attacks.
The approval of garadacimab is based on results from a clinical trial involving 122 people with HAE. The trial found that garadacimab reduced the frequency of angioedema attacks by 78% compared to placebo.
The most common side effects of garadacimab are injection site reactions, headache, and fatigue.
Garadacimab is given as a subcutaneous injection once every four weeks.
The approval of garadacimab is a significant advance in the treatment of HAE. It provides people with HAE with a new option for preventing angioedema attacks and improving their quality of life.
About hereditary angioedema (HAE)
HAE is a rare genetic condition that causes episodes of swelling in the face, limbs, abdomen, and airways. These attacks can be debilitating and potentially life-threatening.
HAE is caused by a deficiency of a protein called C1 inhibitor. C1 inhibitor helps to control the body’s inflammatory response. In people with HAE, the lack of C1 inhibitor leads to uncontrolled inflammation and the development of angioedema attacks.
HAE is inherited in an autosomal dominant manner, which means that a person only needs to inherit one copy of the defective gene from their parents to develop the condition.
About garadacimab (andembry)
Garadacimab is a monoclonal antibody that blocks the action of a protein called kallikrein. Kallikrein is involved in the development of angioedema attacks.
Garadacimab is given as a subcutaneous injection once every four weeks.
Clinical trial results
The approval of garadacimab is based on results from a clinical trial involving 122 people with HAE. The trial found that garadacimab reduced the frequency of angioedema attacks by 78% compared to placebo.
The most common side effects of garadacimab are injection site reactions, headache, and fatigue.
Conclusion
The approval of garadacimab is a significant advance in the treatment of HAE. It provides people with HAE with a new option for preventing angioedema attacks and improving their quality of life.
Garadacimab (andembry) approved to prevent angioedema attacks
The AI has provided us with the news.
I’ve asked Google Gemini the following question, and here’s its response.
UK News and communications a new article on 2025-01-24 12:29 titled “Garadacimab (andembry) approved to prevent angioedema attacks”. Please write a detailed article on this news item, including any relevant information. Answers should be in English.
125